AllianceBernstein’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,214,783
| Closed | -$11.3M | – | 3345 |
|
|
2026
Q1 | $11.3M | Buy |
1,214,783
+1,146,993
| +1,692% | +$16.2M | ﹤0.01% | 1146 |
|
|
2025
Q4 | $632K | Hold |
67,790
| – | – | ﹤0.01% | 2541 |
|
|
2025
Q3 | $478K | Hold |
67,790
| – | – | ﹤0.01% | 2706 |
|
|
2025
Q2 | $441K | Hold |
67,790
| – | – | ﹤0.01% | 2718 |
|
|
2025
Q1 | $538K | Sell |
67,790
-210
| -0.3% | -$2.26K | ﹤0.01% | 2525 |
|
|
2024
Q4 | $862K | Hold |
68,000
| – | – | ﹤0.01% | 2397 |
|
|
2024
Q3 | $947K | Hold |
68,000
| – | – | ﹤0.01% | 2355 |
|
|
2024
Q2 | $937K | Hold |
68,000
| – | – | ﹤0.01% | 2341 |
|
|
2024
Q1 | $1.12M | Buy |
68,000
+16,500
| +32% | +$247K | ﹤0.01% | 2202 |
|
|
2023
Q4 | $752K | Buy |
51,500
+16,430
| +47% | +$199K | ﹤0.01% | 2408 |
|
|
2023
Q3 | $430K | Sell |
35,070
-8,240
| -19% | -$107K | ﹤0.01% | 2646 |
|
|
2023
Q2 | $517K | Buy |
43,310
+5,910
| +16% | +$77.2K | ﹤0.01% | 2625 |
|
|
2023
Q1 | $500K | Sell |
37,400
-4,500
| -11% | -$87.9K | ﹤0.01% | 2577 |
|
|
2022
Q4 | $902K | Buy |
41,900
+3,900
| +10% | +$80K | ﹤0.01% | 2335 |
|
|
2022
Q3 | $761K | Sell |
38,000
-4,400
| -10% | -$93.6K | ﹤0.01% | 2434 |
|
|
2022
Q2 | $759K | Buy |
+42,400
| New | +$438K | ﹤0.01% | 2488 |
|
Other funds holding DAWN
AllianceBernstein's DAWN Position: Q2 2026 in Review
AllianceBernstein sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 1,214,783 shares — an estimated $11.3M sold.
AllianceBernstein first reported a position in DAWN in Q2 2022 and held it in 16 quarters. The position peaked at $11.3M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- AllianceBernstein reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- AllianceBernstein sold 1,214,783 Day One Biopharmaceuticals shares in Q2 2026, an estimated $11.3M.
- AllianceBernstein first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 16 quarters.
- AllianceBernstein's Day One Biopharmaceuticals position peaked at $11.3M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.